for reducing thrombotic risk and fatigue in SLE patients. Further studies are needed to address this issue.

P4 ANTIPHOSPHOLIPID SYNDROME IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION

1Mikel Jordhani, 2Dorina Ruci, 3Ioana Seiti. 4Dept. Internal Medicine, Rheumatology Clinic, UHC Mother Teresa, Tirana; 2Dept. Internal Medicine, Rheumatology Clinic, UHC Mother Teresa, Tirana; 3Dept. Cardiovascular Diseases, Cardiovascular Reanimation Clinic, UHC Mother Teresa, Tirana, Albania

Background Antiphospholipid Syndrome (APS) is a known cause of thrombotic disorders, including Acute Myocardial Infarction (AMI). Although its incidence in AMI patients is not known, it may be an important factor in precipitating infarction, especially in younger adults.

Methods This is a case-control study consisting in 73 patients with Acute Myocardial Infarction, hospitalized at Cardiovascular Reanimation Clinic from 10 December 2015- 10 October 2019. All patients included in the study were from 23 to 50 years old. In the case-group were included 24 patients with Antiphospholipid Syndrome and Acute Myocardial Infarction, and 49 patients were included in the control group, which consisted only in patients with AMI, with no presence of APS. In every patient were gathered data such as complete blood count + ESR, Antinuclear Antibodies (ANA), Anti-cardiolipin antibodies (ACA), C3 and C4 complement fraction, Anti-ds-DNA, CRP and Ejection Fraction (EF) in echocardiography. Female patients were asked about their abortion history. As recommended in the guidelines, in positive results for APS, ACA levels were repeated after 12 weeks in order to establish the diagnosis. All data were gathered and statistically analyzed using Excel 2010 and IBM SPSS.

Results After comparing all gathered data, it was found that the patients with APS and AMI had a more significant tendency to have C3 hypocomplementemia (p=0.006), thrombocytopenia (p=0.002), a lower ejection fraction on transthoracic echocardiography (p=0.04) and a more elevated cytopenia (p=0.002), in comparison to the controls.

Conclusions From our study it was found that APS is not rare in young adults with AMI. It should be always suspected in young adults with AMI. It should be always suspected in young adults with AMI.

Acknowledgements This work was supported by the Arthritis Research and Collaboration Hub (ARCH) Foundation.

P5 RECOGNIZING THE DISEASE, TREATING THE PATIENT: A MIXED-METHOD EVALUATION OF CARE FOR THE ANTIPHOSPHOLIPID SYNDROME (APS) IN THE NETHERLANDS

1Mirthe J Klein Haneveld, 2Caro Lemmen, 3Tammo Brunekreef, 4Marc Bijl, 5Gerard Jansen, 6Karina de Leeuw, 7Julia Spierings, 8Maarten Limper, on behalf of the ARCH study group.

1Dept. of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht; 2Dept. of Internal Medicine and Rheumatology, Martini Hospital, Groningen; 3Dept. of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam; 4Dept. of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, The Netherlands

Abstracts

Purpose This study aims to gain insight into the care provided to patients with antiphospholipid syndrome (APS) in The Netherlands and to identify areas for improvement from the perspective of both patients and clinicians.

Methods APS care was evaluated using qualitative and quantitative methods. Perspectives on APS care were identified using semi-structured interviews with medical specialists, patient focus groups and a cross-sectional, online patient survey. In order to examine differences in medical practice, medical records were reviewed retrospectively regarding clinical and laboratory manifestations, pharmacological treatment and management of disease in six hospitals throughout The Netherlands.

Results Fourteen interviewed medical specialists, fourteen focus group participants and 79 survey respondents participated in the study. 237 patients were included in medical record review. Only one-third of patients were diagnosed with APS within three months after entering specialist care. Diagnosis and management varied between centres and specialists. Almost 10% of triple positive patients did not receive any treatment at the time of medical record review. Major challenges according to specialists and patients were poor recognition of APS by health care professionals, fragmentation of care and lack of accessible, reliable patient education and psychosocial support.

Conclusion This study describes delayed diagnosis, variability in management strategies and a burden placed on patients to orchestrate their own care in APS care in The Netherlands. Of note, almost 10% of triple positive patients did not receive any treatment, despite this group of patients being at the highest risk of recurrent thrombosis.

Acknowledgements This work was supported by The Netherlands Organisation for Health Research and Development (ZonMw) and the Dutch Arthritis Association.

P6 RITUXIMAB EFFICACY IN CAPS

Olena Yakymenko, Viktoria Vasylyets, Viktorko Chochko, Vladimir Savitsky, Natalya Tikhonchuk. Rheumatological Dept., Multifield Medical Center of Odessa national medical university, Odesa, Ukraine

Background Catastrophic antiphospholipid syndrome (CAPS) - thrombotic microvasculopathy, characterized by involvement of systems and organs with formation of their insufficiency. Therapy of glucocorticoids and immunosuppressants with plasmapheresis and intravenous immunoglobulin demonstrates lack of effectiveness. Currently, there are reports of rituximab effectiveness in APS and CAPS, but they are not numerous, especially CAPS.

Methods Assessment of the rituximab effectiveness in patients with resistant CAPS. We present the treatment results of two patients with CAPS, who were treated in our clinic.

Results Patient V., 21, was admitted in the early postpartum period. Diagnosis: Systemic lupus erythematosus, positivity for ANA: ds-DNA, Sm. Secondary antiphospholipid syndrome (positivity for β2-glycoprotein-1, cardiolipin, lupus anticoagulant), catastrophic APS with multorgan failure: epilepsy, sopor, psychosis; acute renal injury, signs of acute respiratory distress syndrome and hypocoagulation. SLEDAI score was 56 points, GAPSS – 17 points. Pulse therapy with methylprednisolone, cyclophosphamide, plasmapheresis and intravenous immunoglobulin wasn’t effective enough. Rituximab course 375 mg/m2 1 time per week for 4 weeks was administered. Manifestations

Lupus & Rheumatology 2020;7(Suppl 1):A1–A131 A31